Brief: Kamada Enters Into A Binding Term Sheet For Contract Manufacturing Of Commercialized Hyper-Immune Globulin Product

Kamada

09/12/2019 12:54

Dec 9 (Reuters) - Kamada Ltd  KMDA.TA :
    * KAMADA ENTERS INTO A BINDING TERM SHEET FOR CONTRACT
MANUFACTURING OF AN FDA APPROVED, COMMERCIALIZED HYPER-IMMUNE
GLOBULIN PRODUCT
    * KAMADA LTD - COMMERCIAL SUPPLY OF 12-YEAR CONTRACT
MANUFACTURING
AGREEMENT IS EXPECTED TO COMMENCE IN EARLY 2023
    * KAMADA LTD -  ESTIMATE HYPER-IMMUNE GLOBULIN PRODUCT
MANUFACTURING WILL ADD ABOUT $8 MILLION TO $10 MILLION TO ANNUAL
REVENUES

Source text for Eikon:  ID:nGNXc2zFpC 
Further company coverage:  KMDA.TA 

 ((Reuters.Briefs@thomsonreuters.com;))